Finance Watch: Karuna, Cerevel And Others Benefit From Improving Biotech Sentiment
Follow-On Offerings Follow Positive Data Readouts
Good news in the biopharma industry and the US economy gave public drug developers the boost they needed to raise cash, including Karuna’s $750m offering. Private company financings slowed during the second week of August, but Prellis and Vector BioPharma raised venture capital.
